Table 4.
DDDs/1000 OBDs of selected antimicrobials used in secondary and tertiary care patients in West London, 2009–13
| Renal inpatients |
Hospital 1 |
Hospital 2 |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2009–10 | 2010–11 | 2011–12 | 2012–13 | 2009–10 | 2010–11 | 2011–12 | 2012–13 | 2009–10 | 2010–11 | 2011–12 | 2012–13 | |
| Ciprofloxacin | 218 (18.1%) | 211 (15.7%) | 197 (14.5%) | 184 (12.9%) | 106 (7.1%) | 120 (7.3%) | 109 (6.4%) | 87 (4.9% | 70 (6.2%) | 77 (5.9%) | 73 (6.0%) | 71 (5.2%) |
| Amoxicillin/clavulanate | 127 (10.5%) | 138 (10.2%) | 177 (13.0%) | 158 (11.1%) | 305 (20.4%) | 354 (21.5%) | 394 (23.2%) | 384 (21.6%) | 243 (21.5%) | 248 (19.1%) | 257 (21.1%) | 286 (21.0%) |
| Piperacillin/tazobactam | 114 (9.5%) | 135 (10.0%) | 158 (11.6%) | 147 (10.3%) | 87 (5.8%) | 110 (6.7%) | 104 (6.1%) | 110 (6.2%) | 48 (4.2%) | 65 (5.0%) | 64 (5.2%) | 72 (5.3%) |
| Meropenem | 142 (11.8%) | 143 (10.7%) | 76 (5.6%) | 85 (6.0%) | 77 (5.2%) | 112 (6.8%) | 100 (5.9%) | 106 (6.0%) | 39 (3.5%) | 53 (4.1%) | 46 (3.8%) | 61 (4.5%) |
| Cumulativea | 49.8% (49.3–50.3) | 46.5% (46.1–47.0) | 44.6% (44.1–45.1) | 40.3% (39.8–40.8) | 38.5% (38.3–38.8) | 42.3% (42.0–42.6) | 41.6% (41.3–41.8) | 38.7% (38.5–39.0) | 35.2% (35.1–35.5) | 34.2% (34.0–34.4) | 36.2% (35.9–36.4) | 36.1% (35.8–36.3) |
Percentages in parentheses indicate the consumption of that agent as a proportion of all antimicrobials used.
aProportion as a percentage of all antimicrobials prescribed (95% CI).